These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 26068491)

  • 1. Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy.
    Pollom EL; Deng L; Pai RK; Brown JM; Giaccia A; Loo BW; Shultz DB; Le QT; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):568-76. PubMed ID: 26068491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT).
    Barney BM; Markovic SN; Laack NN; Miller RC; Sarkaria JN; Macdonald OK; Bauer HJ; Olivier KR
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):73-80. PubMed ID: 23920388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining antiangiogenics to overcome resistance: rationale and clinical experience.
    Moreno Garcia V; Basu B; Molife LR; Kaye SB
    Clin Cancer Res; 2012 Jul; 18(14):3750-61. PubMed ID: 22547772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review.
    Kroeze SG; Fritz C; Hoyer M; Lo SS; Ricardi U; Sahgal A; Stahel R; Stupp R; Guckenberger M
    Cancer Treat Rev; 2017 Feb; 53():25-37. PubMed ID: 28056412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
    Mahalingam D; Malik L; Beeram M; Rodon J; Sankhala K; Mita A; Benjamin D; Ketchum N; Michalek J; Tolcher A; Wright J; Sarantopoulos J
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):77-84. PubMed ID: 24817603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.
    Cabrera AR; Cuneo KC; Desjardins A; Sampson JH; McSherry F; Herndon JE; Peters KB; Allen K; Hoang JK; Chang Z; Craciunescu O; Vredenburgh JJ; Friedman HS; Kirkpatrick JP
    Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):873-9. PubMed ID: 23725997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combination of stereotactic irradiation and chemotherapy or targeted therapies: state of the art and preliminary recommendations].
    Thariat J; Kirova Y; Milano G; Mornex F
    Cancer Radiother; 2014; 18(4):270-9. PubMed ID: 25053603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
    Thornton AD; Ravn P; Winslet M; Chester K
    Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
    Brade AM; Ng S; Brierley J; Kim J; Dinniwell R; Ringash J; Wong RR; Cho C; Knox J; Dawson LA
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):580-7. PubMed ID: 26867886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
    Reinacher-Schick A; Pohl M; Schmiegel W
    Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab in the treatment of breast cancer.
    Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
    Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of steroid refractory, Gamma Knife related radiation necrosis with bevacizumab: case report and review of the literature.
    Sanborn MR; Danish SF; Rosenfeld MR; O'Rourke D; Lee JY
    Clin Neurol Neurosurg; 2011 Nov; 113(9):798-802. PubMed ID: 21906869
    [No Abstract]   [Full Text] [Related]  

  • 17. Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes.
    Poorvu PD; Sadow CA; Townamchai K; Damato AL; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1262-8. PubMed ID: 23182395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.
    Limaverde-Sousa G; Sternberg C; Ferreira CG
    Cancer Treat Rev; 2014 May; 40(4):548-57. PubMed ID: 24360358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic agents in cancer therapy.
    Lenz HJ
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):17-25. PubMed ID: 15934499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.